复方促肾上腺皮质激素注射液治疗难治性皮肤型皮肌炎的有效性与安全性:一项前瞻性开放标签研究
这项前瞻性开放标签研究纳入皮肤活动度中重度(CDASI-A>14)且既往使用≥2种系统药物的皮肤型皮肌炎患者,给予复方促肾上腺皮质激素注射液80单位每周两次共6个月。15例完成者6个月时CDASI-A、PGA、PtGSS及DLQI均较基线有统计学显著改善,不良反应轻微。作者认为该药对难治性皮肤型皮肌炎有效、安全且耐受良好。
要点
- 15例完成6个月治疗者CDASI-A中位数由基线19.0降至6个月时10.0。
- PGA活动度中位数由2.5/10降至0.8/10,PtGSS与DLQI亦改善。
- 不良反应轻微,作者认为该药对难治性皮肤型皮肌炎有效且耐受良好。
核心结论
- 复方促肾上腺皮质激素注射液治疗使皮肤型皮肌炎活动度和生活质量获得统计学显著且有临床意义的改善。
- 作者认为该药对难治性皮肤型皮肌炎患者是有效、安全且耐受良好的治疗。
研究设计与样本
- 前瞻性、开放标签试验,纳入皮肤活动度中重度(CDASI-A>14)且既往使用≥2种系统药物的皮肌炎患者。
- 患者接受复方促肾上腺皮质激素注射液80单位每周两次,持续6个月。
- 主要结局为6个月时CDASI-A和PGA评分的显著下降。
- 共19例入组,15例(11例女性、4例男性;7例经典型、8例无肌病型)完成6个月治疗。
- 临床试验注册号:NCT01906372。
主要发现
- 入组时既往系统药物使用中位数为3.0种,入组时正在使用系统药物中位数为2.0种。
- 基线CDASI-A中位数为19.0,PGA活动度中位数为2.5/10,PtGSS中位数为3.0/10,DLQI中位数为7.0/10。
- 6个月时CDASI-A中位数为10.0、PGA中位数为0.8/10、PtGSS中位数为7.0、DLQI中位数为2.0,均较基线有统计学显著改善。
- 不良反应轻微。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cutaneous dermatomyositis (DM) is often refractory to multiple medications. Repository corticotropin injection (RCI) is FDA-approved for DM, but little is known about its efficacy and safety for treating cutaneous DM. We conducted a prospective, open-label trial assessing efficacy and safety of RCI for treating refractory cutaneous DM. METHODS: DM patients with moderate-to-severe cutaneous activity [Cutaneous Dermatomyositis Disease Area and Severity Index activity (CDASI-A)] >14 despite prior treatment with ≥2 systemic agents were enrolled. Patients were initiated on 80 u RCI twice weekly for 6 months. Primary outcomes included significant decreases in CDASI-A and Physician's Global Assessment (PGA) scores at 6 months. RESULTS: Of 19 patients enrolled, 15 patients (11 females, four males) with DM (seven classic, eight amyopathic) completed 6 months of RCI treatment. Patients were treated with a median 3.0 systemic medications prior to enrolment and were taking a median of 2.0 systemic medications at enrolment. Median baseline CDASI-A score was 19.0 and median PGA activity score was 2.5/10. For patient-reported outcomes, baseline median patient global skin score (PtGSS) was 3.0/10 and median dermatology life quality index (DLQI) score was 7.0/10. At 6 months, there were statistically significant improvements in CDASI-A scores (median = 10.0), PGA scores (median = 0.8/10), PtGSS scores (median = 7.0) and DLQI scores (median = 2.0), among others. Adverse effects were mild. CONCLUSIONS: RCI treatment resulted in statistically significant and clinically meaningful improvement in cutaneous DM activity and quality of life. Our results suggest RCI is an effective, safe and well-tolerated treatment for patients with refractory cutaneous dermatomyositis. CLINICAL TRIAL REGISTRATION: This clinical trial was registered with ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT01906372).
引用
- Fernandez AP, Gallop J, Polly S, et al. Efficacy and safety of repository corticotropin injection for refractory cutaneous dermatomyositis: a prospective, open-label study. Rheumatology (Oxford). 2024. PMID: 37941470. doi:10.1093/rheumatology/kead595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。